Diseases / Alopecia
Alopecia
DiseaseAlopecia (hair loss) is loss of hair from part of the scalp or body and can range from small patches to diffuse or complete loss. Common forms include male/female pattern hair loss, alopecia areata, and telogen effluvium.
- Trials
- 464
- Recruiting
- 48
- Completed
- 226
- With results
- 62
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Unknown | Available | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | 2 | — | — | 7 | 1 | 1 | 2 | — | 14 |
| Phase 1 | 1 | — | — | 1 | 20 | 3 | — | 6 | — | 31 |
| Phase 1/2 | 6 | 3 | 1 | — | 8 | 1 | 1 | 6 | — | 26 |
| Phase 2 | 4 | 5 | — | 5 | 52 | 4 | 4 | 4 | — | 78 |
| Phase 2/3 | — | 3 | — | 1 | 3 | — | — | 1 | — | 8 |
| Phase 3 | 7 | 6 | — | 3 | 25 | — | 1 | 4 | — | 46 |
| Phase 4 | 1 | 2 | — | — | 2 | — | 2 | 7 | — | 14 |
| Not applicable | 22 | 12 | 3 | 13 | 87 | 9 | 11 | 38 | — | 195 |
| Unknown | 6 | 3 | 1 | 2 | 22 | 4 | 2 | 11 | 1 | 52 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Alopecia | 14 | 31 | 26 | 78 | 8 | 46 | 14 | 195 | 52 | 464 |
| Alopecia Areata | 2 | 2 | 1 | 12 | 1 | 5 | 1 | 5 | 7 | 36 |
| Breast Neoplasms | — | 1 | — | 1 | — | — | — | 12 | 2 | 16 |
| Hair Diseases | — | 1 | 1 | — | 1 | 5 | 1 | 3 | 3 | 15 |
| Alopecia universalis | — | — | — | 7 | 1 | 2 | — | 1 | 3 | 14 |
| Skin Diseases | — | 1 | 2 | — | — | 2 | — | 1 | 2 | 8 |
| Acne Vulgaris | — | 2 | — | 1 | — | — | — | 1 | 3 | 7 |
| Lichen Planus | 1 | — | — | 1 | — | — | — | — | 4 | 6 |
| Autoimmune Diseases | — | — | — | — | — | — | — | 1 | 4 | 5 |
| COVID-19 | — | — | — | — | — | — | — | 1 | 3 | 4 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Aderans Research Institute | 11 | 0 |
| 2 | Applied Biology, Inc. | 9 | 3 |
| 3 | Suzhou Kintor Pharmaceutical Inc, | 9 | 2 |
| 4 | Allergan | 7 | 0 |
| 5 | Cairo University | 7 | 1 |
| 6 | Ablon Skin Institute Research Center | 6 | 0 |
| 7 | Assiut University | 6 | 0 |
| 8 | NovoBliss Research Pvt Ltd | 6 | 0 |
| 9 | Pfizer | 6 | 3 |
| 10 | GlaxoSmithKline | 5 | 3 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Minoxidil | 50 |
| 2 | Finasteride | 13 |
| 3 | Solutions | 13 |
| 4 | Sodium Chloride | 9 |
| 5 | Dutasteride | 7 |
| 6 | Dietary Supplements | 5 |
| 7 | Injections | 5 |
| 8 | Bimatoprost | 4 |
| 9 | Biotin | 4 |
| 10 | Low-Level Light Therapy | 4 |
Evidence
- Results reported
- 27.4%62 of 226 completed
- Published
- 5.8%13 of 226 completed
- Primary endpoint met
- 72.5%29 of 40 analyses
- Median months to report
- 15
Documents disclosed
Trial profile
- Median enrollment
- 50
- Median duration
- 14months
- Countries
- 51
- Study sites
- 1580
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 29
- Phase 1
- 35
- Phase 1/2
- 35
- Phase 2
- 70
- Phase 2/3
- 638
- Phase 3
- 331
- Phase 4
- 53
- Not applicable
- 43
- Unknown
- 90
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New York | United States | 41 |
| 2 | Minneapolis | United States | 21 |
| 3 | Portland | United States | 21 |
| 4 | Houston | United States | 20 |
| 5 | Austin | United States | 19 |
| 6 | Miami | United States | 19 |
| 7 | Berlin | Germany | 16 |
| 8 | Beijing | China | 15 |
| 9 | Los Angeles | United States | 15 |
| 10 | Seoul | South Korea | 15 |
Terminations
- Terminated
- 22
- Withdrawn
- 22
- Stopped for recruitment
- 1.9%9 of 464 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT02849470 Withdrawn | Withdrawn | Terminated by researchers without submission of patient admission to study. COVID complicated continuing search for qualified candidates | 2028-07-31 |
| NCT06932393 Terminated | Terminated | Per updated regulatory requirements, the site is ineligible to proceed. The clinical institution office has terminated the project. | 2026-04-17 |
| NCT05129254 Withdrawn | Withdrawn | Study not initiated. | 2025-12-31 |
| NCT06854575 Terminated | Terminated | Sponsor Business Decision | 2025-09-15 |
| NCT06560385 Terminated | Terminated | No enough subjects within the recruitment period | 2025-08-18 |
| NCT06497764 Withdrawn | Withdrawn | Departmental research administration decided to close the study as there had been no enrollment. No participants were screened or consented. | 2025-07-01 |
| NCT05426629 Withdrawn | Withdrawn | IRB closed | 2025-04-21 |
| NCT04882969 Withdrawn | Withdrawn | Changed Indication | 2024-12-31 |
| NCT06484881 Withdrawn | Withdrawn | Concern about formulation patent | 2024-10-10 |
| NCT04517864 Terminated | Terminated | For business reasons | 2024-05-07 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: